University of California

Medical Research Council

Other

Cambridge Antibody Technology Limited

Fox Chase Cancer Center

Medimmune Limited

The University of Queensland

Expert Viewpoint, LLC

Dendrocyte Biotech Pty Ltd

Merrimack Pharmaceuticals, Inc.

Kira Biotech Pty Limited

Centre National De La Recherche Scientifique

Université Paris—sud

Ecole Normale Superieure De Cachan

Transbio Ltd

James David Marks

Gregory Paul Winter

Andrew David Griffiths

John Gerald McCafferty

Bin Liu

Dmitri B Kirpotin

Jianlong Lou

Anthony Richard Pope

Kevin Stuart Johnson

Ronald Henry Jackson

David John Chiswell

Timothy Peter Bonnert

Timothy Piers Clackson

Kaspar Philipp Holliger

Jody Lynn Baron

Yu Zhou

Stephen L Nishimura

Geoffrey Walter Grigg

Maria Consuelo Garcia Rodriguez

Hendricus Renerus Jacobus Mattheus Hoogenboom

Isin N Geren

Henricus Renerus Jacobus Mattheus Hoogenboom

Louis M Weiner

Gregory P Adams

Yifan Cheng

Eva M Horak

Marie Alix Poul

Anthony Cormier

Brian Timothy McGuinness

Magnus Malmqvist

Derek Nigel John Hart

David John Munster

Trent Phillip Munro

Robert Schier

Robert E Reiter

Anna M Wu

Ping Tsui

Yanli Wu

Hendricus Renerus Hoogenboom

Scott Bidlingmaier

Marie-Alix Poul

Terence Derek Prospero

Shenping Wu

Naoki Takasaka

Peter Amersdorfer

Ali Razai

Therese Ann Seldon

Martina Louise Jones

Stephen Michael Mahler

Maria Consuelo Garcia

Eric J Lepin

Melody G Campbell

Saburo Ito

Hendricus Renerus Jacobus Matheus Hoogenboom

Shude Yan

Kaspar-Philipp Holliger

Xiaodong Zhu

Ulrik B Nielson

Ross Bane Fulton

Eric M Tam

James Frank Sampson

Marco Muda

Henricus Renerus Hoogenboom

Eunice Yu Zhou

Kasper Philipp Holliger

Robert Weaver

Jeremy Shao

Kaspar-Philip Holliger

Baltazar Becerril

Zhengda Sun

Jianbo Dong

Dimitri B Kirpotin

Hendricus Reneus Jacobus Mattheus Hoogenboom

Hendricus Renerus Jacobus M Hoogenboom

Ulrik B Nielsen

Stephen Nishimura

Lynne Murray

Jody L Baron

Ronan Philippe Crepin

The present disclosure provides antibodies that specifically bind toneurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralizeneurotoxin and are therefore also useful in the treatment of botulism.

Antibodies for botulinum neurotoxins

The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases.

Anti-TNFR2 antibodies and uses thereof

Antibodies that bind to αvβ8 are provided.

Antibodies that bind integrin αvβ8 and uses thereof

New antibodies and methods of use are described.

Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.

Anti-CD83 antibodies and use thereof

Antibodies that bind to &#x3b1;&#x3bd;&#x3b2;8 are provided.

Antibodies that bind integrin AVB8 and uses thereof

Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy

The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

Antibodies to botulinum neurotoxins

Provided is an antibody that specifically binds human &#x3b1;v&#x3b2;&#x3b2; and blocks binding of TGFp peptide to &#x3b1;v&#x3b2;8, wherein the antibody binds to the specificity determining loop (SDL) of human &#x3b2;8. In some embodiments, the antibody further binds to one, two, or all three of the human av-head domain, the al helix of human &#x3b2;8, or the al helix of human &#x3b2;8. In some embodiments, the antibody is humanized or chimeric. In some embodiments, the antibody is linked to a detectable label. Also provided is a method of enhancing an immune response in a human individual, comprising administering a sufficient amount of the antibody to the individual, thereby enhancing an immune response. Also provided are pharmaceutical compositions comprising the anti-&#x3b1;v&#x3b2;&#x3b2; antibodies or antigen-binding molecules thereof.

Neutralizing antibodies to the &#x3b1;v&#x3b2;8 integrin complex for immunotherapy

This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Antibodies that neutralize botulinum neurotoxins

The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis or prognosis.

This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

Growing community of inventors

Kensington, CA, United States of America

James David Marks